Questcor's (NASDAQ:QCOR) flagship drug, Acthar, has been around for over 60 years. Despite its age, the company discovered a way to breathe new life into sales of this old drug. So, why does this remain one of the most controversial companies in the health care space today? In this video, Motley Fool health care bureau chief Brenton Flynn takes us through some of his likes and dislikes with Questcor.
The pros and cons of this controversial biotech.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
Why Novo Nordisk Topped the Market Today
Buying the Dip in These 3 Undervalued Dividend Stocks
Elevance Health Beats EPS Estimates, Raises 2024 Guidance
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
606%
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.